PRME (Prime Medicine) Short-Term Debt: $0.00 Mil (As of Mar. 2026)


PRME Prime Medicine Inc PRME
28 GF Score
Price $3.87
! 5 Warning Signs
View Full Analysis

What is Prime Medicine Short-Term Debt?

Prime Medicine PRME -0.39% 28 Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates PRME with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

Prime Medicine's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Prime Medicine Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Prime Medicine Short-Term Debt Related Terms

Prime Medicine Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Prime Medicine's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prime Medicine Short-Term Debt Chart

Prime Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Prime Medicine Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PRME
28GF Score
Prime Medicine Inc PRME
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Prime Medicine (PRME) has a Short-Term Debt of $0.00 Mil as of Mar. 2026.
Is Prime Medicine's Short-Term Debt too high?
Prime Medicine's current Short-Term Debt is $0.00 Mil. Overall, Prime Medicine has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's Short-Term Debt compare to EIKN and CRMD?
Prime Medicine's Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Prime Medicine's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Prime Medicine's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Prime Medicine (PRME), the current Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prime Medicine Business Description

Address 60 First Street, Cambridge, MA, USA, 02141
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
28GF Score

Get the complete analysis for PRME

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.87
Price